On July 7, 2023, BioXcel Therapeutics, Inc. was sued for violations of the federal securities laws in the United States District Court for the District of Connecticut on behalf of investors who purchased or otherwise acquired BioXcel securities between December 15, 2021 and June 28, 2023, inclusive (the “Class Period”).
We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.